The invention relates to antibodies against the Platelet Derived Growth Factor Receptor beta (PDGFR ?), and the use thereof in diagnostic and/or therapeutic applications. In particular, it provides a (VHH) antibody that specifically binds PDGFR ? with an apparent binding affinity of less than 10 nM, preferably less than 5 nM, and which does not activate PDGFR ?. Also provided are PDGFR ? antibodies and conjugates thereof, and their application in the targeted delivery of a diagnostic agent, a therapeutic agent or a combination thereof to a tissue in a subject, in particular to fibrotic tissue comprising activated myofibroblasts.

Provided are a conjugate including an EGFR inhibitor that enables treatment and diagnosis of epidermal growth factor receptor (EGFR)-overexpressing tumors including resistant tumors, a method that enables drug delivery treatment and diagnosis of EGFR-overexpressing tumors using the conjugate, and a method of preparing the conjugate.

Provided are anti-hVEGFR2 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

An HER2 affibody .sup.99mTc marker composition and application thereof are provided, which relates to the field of radiopharmaceuticals and nuclear medicine. The HER2 affibody .sup.99mTc marker composition contains HEPES, sodium glucoheptonate, vitamin C, cysteine, stannous chloride and an HER2 affibody.

A storage method according to an aspect of the present invention includes storing an intermediate of a radiopharmaceutical composition in an acetate buffer. The intermediate is a complex of a 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15), 11, 13-triene-3,6,9-triacetic acid (PCTA) and an anti-epidermal growth factor receptor antibody (anti-EGFR antibody). The intermediate is stored for a storage period of not less than 24 hours.

The present invention relates to conjugates comprising a protein and multivalent cell-penetrating peptide(s), each multivalent cell-penetrating peptide comprising at least two cell-penetrating peptides, wherein the multivalent cell-penetrating peptide(s) is/are covalently attached to the protein. The present invention furthermore relates to a method of generating the conjugates and to their medical uses, in particular their use in the diagnosis, prevention and/or treatment of diseases. The present invention relates to methods of diagnosis, prevention and/or treatment of diseases, comprising administering the conjugates of the invention to a patient.

The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.

The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided

Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.

The present invention is directed to human monoclonal antibodies that bind to Anaplastic Lymphoma Kinase (ALK).